Clinical Trial Detail

NCT ID NCT01777776
Title Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

Encorafenib

Encorafenib + Ribociclib

Age Groups: adult

Additional content available in CKB BOOST